MT2021-25: Phase I/II clinical study of GDA-201, allogeneic Natural Killer cells, for patients withrelapsed/refractory B-Cell Non-Hodgkin Lymphoma

Project: Research project

Project Details

Description

MT2021-25: Phase I/II clinical study of GDA-201, allogeneic Natural Killer cells, for patients with relapsed/refractory B-Cell Non-Hodgkin Lymphoma
StatusActive
Effective start/end date9/28/21 → 10/1/26

Funding

  • GAMIDA CELL LTD.
View all
View less

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint